ID   LOXL3_HUMAN             Reviewed;         753 AA.
AC   P58215; D6W5J1; Q2EHP2; Q6IPL7; Q96RS1;
DT   11-JUL-2001, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2001, sequence version 1.
DT   28-JUN-2023, entry version 183.
DE   RecName: Full=Lysyl oxidase homolog 3 {ECO:0000305};
DE            EC=1.4.3.- {ECO:0000269|PubMed:28065600};
DE            EC=1.4.3.13 {ECO:0000269|PubMed:28065600};
DE   AltName: Full=Lysyl oxidase-like protein 3 {ECO:0000303|PubMed:11386757};
DE   Flags: Precursor;
GN   Name=LOXL3 {ECO:0000303|PubMed:11386757, ECO:0000312|HGNC:HGNC:13869};
GN   Synonyms=LOXL {ECO:0000303|PubMed:11284725};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11284725; DOI=10.1042/0264-6021:3550381;
RA   Maki J.M., Kivirikko K.I.;
RT   "Cloning and characterization of a fourth human lysyl oxidase isoenzyme.";
RL   Biochem. J. 355:381-387(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11386757; DOI=10.1006/geno.2001.6545;
RA   Jourdan-Le Saux C., Tomshe A., Ujfalusi A., Jia L., Csiszar K.;
RT   "Central nervous system, uterus, heart, and leukocyte expression of the
RT   LOXL3 gene, encoding a novel lysyl oxidase-like protein.";
RL   Genomics 74:211-218(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11334717; DOI=10.1016/s0945-053x(01)00124-x;
RA   Huang Y., Dai J., Tang R., Zhao W., Zhou Z., Wang W., Ying K., Xie Y.,
RA   Mao Y.;
RT   "Cloning and characterization of a human lysyl oxidase-like 3 gene
RT   (hLOXL3).";
RL   Matrix Biol. 20:153-157(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORMS 1 AND 2),
RP   SUBCELLULAR LOCATION (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=17018530; DOI=10.1074/jbc.m600977200;
RA   Lee J.-E., Kim Y.;
RT   "A tissue-specific variant of the human lysyl oxidase-like protein 3
RT   (LOXL3) functions as an amine oxidase with substrate specificity.";
RL   J. Biol. Chem. 281:37282-37290(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INVOLVEMENT IN STICKLER SYNDROME, AND VARIANT TYR-676.
RX   PubMed=25663169; DOI=10.1007/s00439-015-1531-z;
RA   Alzahrani F., Al Hazzaa S.A., Tayeb H., Alkuraya F.S.;
RT   "LOXL3, encoding lysyl oxidase-like 3, is mutated in a family with
RT   autosomal recessive Stickler syndrome.";
RL   Hum. Genet. 134:451-453(2015).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=26218558; DOI=10.14670/hh-11-649;
RA   Dudakova L., Sasaki T., Liskova P., Palos M., Jirsova K.;
RT   "The presence of lysyl oxidase-like enzymes in human control and
RT   keratoconic corneas.";
RL   Histol. Histopathol. 31:63-71(2016).
RN   [10]
RP   INVOLVEMENT IN MYP28.
RX   PubMed=26957899;
RA   Li J., Gao B., Xiao X., Li S., Jia X., Sun W., Guo X., Zhang Q.;
RT   "Exome sequencing identified null mutations in LOXL3 associated with early-
RT   onset high myopia.";
RL   Mol. Vis. 22:161-167(2016).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, INTERACTION WITH STAT3, AND MUTAGENESIS OF CYS-83; CYS-214;
RP   CYS-345; CYS-376; CYS-446; CYS-459; CYS-492 AND 607-HIS--HIS-609.
RX   PubMed=28065600; DOI=10.1016/j.molcel.2016.12.002;
RA   Ma L., Huang C., Wang X.J., Xin D.E., Wang L.S., Zou Q.C., Zhang Y.S.,
RA   Tan M.D., Wang Y.M., Zhao T.C., Chatterjee D., Altura R.A., Wang C.,
RA   Xu Y.S., Yang J.H., Fan Y.S., Han B.H., Si J., Zhang X., Cheng J.,
RA   Chang Z., Chin Y.E.;
RT   "Lysyl oxidase 3 is a dual-specificity enzyme involved in STAT3
RT   deacetylation and deacetylimination modulation.";
RL   Mol. Cell 65:296-309(2017).
RN   [12]
RP   INVOLVEMENT IN MYP28.
RX   PubMed=33456446; DOI=10.3389/fgene.2020.580484;
RA   Maddirevula S., Shamseldin H.E., Sirr A., Alabdi L., Lo R.S., Ewida N.,
RA   Al-Qahtani M., Hashem M., Abdulwahab F., Aboyousef O., Kaya N., Monies D.,
RA   Salem M.H., Al Harbi N., Aldhalaan H.M., Alzaidan H., Almanea H.M.,
RA   Alsalamah A.K., Al Mutairi F., Ismail S., Abdel-Salam G.M.H., Alhashem A.,
RA   Asery A., Faqeih E., Al-Qassmi A., Al-Hamoudi W., Algoufi T., Shagrani M.,
RA   Dudley A.M., Alkuraya F.S.;
RT   "Exploiting the Autozygome to Support Previously Published Mendelian Gene-
RT   Disease Associations: An Update.";
RL   Front. Genet. 11:580484-580484(2020).
CC   -!- FUNCTION: Protein-lysine 6-oxidase that mediates the oxidation of
CC       peptidyl lysine residues to allysine in target proteins
CC       (PubMed:17018530, PubMed:28065600). Catalyzes the post-translational
CC       oxidative deamination of peptidyl lysine residues in precursors of
CC       elastin and different types of collagens, a prerequisite in the
CC       formation of cross-links between collagens and elastin
CC       (PubMed:17018530). Required for somite boundary formation by catalyzing
CC       oxidation of fibronectin (FN1), enhancing integrin signaling in
CC       myofibers and their adhesion to the myotendinous junction (MTJ) (By
CC       similarity). Acts as a regulator of inflammatory response by inhibiting
CC       differentiation of naive CD4(+) T-cells into T-helper Th17 or
CC       regulatory T-cells (Treg): acts by interacting with STAT3 in the
CC       nucleus and catalyzing both deacetylation and oxidation of lysine
CC       residues on STAT3, leading to disrupt STAT3 dimerization and inhibit
CC       STAT3 transcription activity (PubMed:28065600). Oxidation of lysine
CC       residues to allysine on STAT3 preferentially takes place on lysine
CC       residues that are acetylated (PubMed:28065600). Also able to catalyze
CC       deacetylation of lysine residues on STAT3 (PubMed:28065600).
CC       {ECO:0000250|UniProtKB:Q9Z175, ECO:0000269|PubMed:17018530,
CC       ECO:0000269|PubMed:28065600}.
CC   -!- FUNCTION: [Isoform 1]: Shows protein-lysine 6-oxidase activity toward
CC       elastin and different types of collagens, with the highest activity
CC       toward collagen type VIII (PubMed:17018530).
CC       {ECO:0000269|PubMed:17018530}.
CC   -!- FUNCTION: [Isoform 2]: Shows protein-lysine 6-oxidase activity toward
CC       elastin and different types of collagens, with the highest activity
CC       toward collagen type IV (PubMed:17018530).
CC       {ECO:0000269|PubMed:17018530}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + L-lysyl-[protein] + O2 = (S)-2-amino-6-oxohexanoyl-
CC         [protein] + H2O2 + NH4(+); Xref=Rhea:RHEA:24544, Rhea:RHEA-COMP:9752,
CC         Rhea:RHEA-COMP:12448, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:28938, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:131803; EC=1.4.3.13;
CC         Evidence={ECO:0000269|PubMed:28065600};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N(6)-acetyl-L-lysyl-[protein] + O2 = (S)-2-amino-6-
CC         oxohexanoyl-[protein] + acetamide + H2O2; Xref=Rhea:RHEA:51648,
CC         Rhea:RHEA-COMP:10731, Rhea:RHEA-COMP:12448, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:16240, ChEBI:CHEBI:27856,
CC         ChEBI:CHEBI:61930, ChEBI:CHEBI:131803;
CC         Evidence={ECO:0000269|PubMed:28065600};
CC   -!- COFACTOR:
CC       Name=Cu cation; Xref=ChEBI:CHEBI:23378;
CC         Evidence={ECO:0000250|UniProtKB:P16636};
CC   -!- COFACTOR:
CC       Name=lysine tyrosylquinone residue; Xref=ChEBI:CHEBI:20489;
CC         Evidence={ECO:0000250|UniProtKB:P33072};
CC       Note=Contains 1 lysine tyrosylquinone. {ECO:0000250|UniProtKB:P33072};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.72 uM for STAT3 acetylated at 'Lys-685' (for deacetylation
CC         activity) {ECO:0000269|PubMed:28065600};
CC         KM=1.59 uM for STAT3 acetylated at 'Lys-685' (for lysine 6-oxidase
CC         activity) {ECO:0000269|PubMed:28065600};
CC         Note=kcat is 0.058 sec(-1) with STAT3 acetylated at 'Lys-685' (for
CC         deacetylation activity). kcat is 0.022 sec(-1) with STAT3 acetylated
CC         at 'Lys-685' (for lysine 6-oxidase activity).
CC         {ECO:0000269|PubMed:28065600};
CC   -!- SUBUNIT: Interacts with STAT3 (PubMed:28065600).
CC       {ECO:0000269|PubMed:28065600}.
CC   -!- INTERACTION:
CC       P58215; Q7TSK7: Adamtsl2; Xeno; NbExp=2; IntAct=EBI-723960, EBI-25406979;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space
CC       {ECO:0000250|UniProtKB:Q9Z175}. Cytoplasm
CC       {ECO:0000269|PubMed:28065600}. Nucleus {ECO:0000269|PubMed:28065600}.
CC       Note=It is unclear how LOXL3 is both intracellular (cytoplasmic and
CC       nuclear) and extracellular: it contains a clear signal sequence and is
CC       predicted to localize in the extracellular medium. However, the
CC       intracellular location is clearly reported and at least another protein
CC       of the family (LOXL2) also has intracellular and extracellular
CC       localization despite the presence of a signal sequence
CC       (PubMed:28065600). {ECO:0000269|PubMed:28065600}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Secreted, extracellular space
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:17018530}. Secreted, extracellular space
CC       {ECO:0000269|PubMed:17018530}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P58215-1; Sequence=Displayed;
CC       Name=2; Synonyms=LOXL3-sv1 {ECO:0000303|PubMed:17018530};
CC         IsoId=P58215-2; Sequence=VSP_054417;
CC       Name=3;
CC         IsoId=P58215-3; Sequence=VSP_054418;
CC   -!- TISSUE SPECIFICITY: Isoform 1: Predominantly detected in the heart,
CC       placenta, lung, and small intestine (PubMed:17018530). Isoform 2:
CC       Highly detected in the kidney, pancreas, spleen, and thymus, and is
CC       absent in lung (PubMed:17018530). In eye, present in all layers of
CC       corneas as well as in the limbus and conjunctiva (at protein level)
CC       (PubMed:26218558). {ECO:0000269|PubMed:17018530,
CC       ECO:0000269|PubMed:26218558}.
CC   -!- PTM: The lysine tyrosylquinone cross-link (LTQ) is generated by
CC       condensation of the epsilon-amino group of a lysine with a topaquinone
CC       produced by oxidation of tyrosine. {ECO:0000250|UniProtKB:P33072}.
CC   -!- DISEASE: Note=Defects in LOXL3 are found in a family with an autosomal
CC       recessive form of Stickler syndrome, an inherited disorder that
CC       associates ocular signs with more or less complete forms of Pierre
CC       Robin sequence and sensorineural deafness (PubMed:25663169). Pierre
CC       Robin sequence includes an opening in the roof of the mouth (a cleft
CC       palate) (PubMed:25663169). The degree of hearing loss varies among
CC       affected individuals and may become more severe over time
CC       (PubMed:25663169). Syndrome expressivity is variable (PubMed:25663169).
CC       Ocular disorders include non-progressive myopia with associated
CC       chorioretinal degeneration (PubMed:25663169).
CC       {ECO:0000269|PubMed:25663169}.
CC   -!- DISEASE: Myopia 28, autosomal recessive (MYP28) [MIM:619781]: A form of
CC       myopia, a refractive error of the eye, in which parallel rays from a
CC       distant object come to focus in front of the retina, vision being
CC       better for near objects than for far. MYP28 patients are affected by
CC       early-onset high myopia in the first decade of life. Retinal detachment
CC       may occur, and early-onset cataract has been reported.
CC       {ECO:0000269|PubMed:26957899, ECO:0000269|PubMed:33456446}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Misses three SRCR domains. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the lysyl oxidase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/44000/LOXL3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF282619; AAK51671.1; -; mRNA.
DR   EMBL; AF311313; AAK63205.1; -; mRNA.
DR   EMBL; AF284815; AAK91134.1; -; mRNA.
DR   EMBL; DQ378059; ABD23013.1; -; mRNA.
DR   EMBL; AC005033; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005041; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471053; EAW99615.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAW99616.1; -; Genomic_DNA.
DR   EMBL; BC071865; AAH71865.1; -; mRNA.
DR   CCDS; CCDS1953.1; -. [P58215-1]
DR   CCDS; CCDS74527.1; -. [P58215-3]
DR   RefSeq; NP_001276093.1; NM_001289164.2. [P58215-3]
DR   RefSeq; NP_001276094.1; NM_001289165.1. [P58215-2]
DR   RefSeq; NP_115992.1; NM_032603.4. [P58215-1]
DR   RefSeq; XP_011531436.1; XM_011533134.2. [P58215-1]
DR   RefSeq; XP_016860601.1; XM_017005112.1.
DR   AlphaFoldDB; P58215; -.
DR   SMR; P58215; -.
DR   BioGRID; 124210; 24.
DR   IntAct; P58215; 5.
DR   STRING; 9606.ENSP00000264094; -.
DR   BindingDB; P58215; -.
DR   ChEMBL; CHEMBL4105989; -.
DR   GlyConnect; 1481; 3 N-Linked glycans (1 site).
DR   GlyCosmos; P58215; 5 sites, 3 glycans.
DR   GlyGen; P58215; 5 sites, 3 N-linked glycans (1 site).
DR   iPTMnet; P58215; -.
DR   PhosphoSitePlus; P58215; -.
DR   BioMuta; LOXL3; -.
DR   DMDM; 14916616; -.
DR   EPD; P58215; -.
DR   jPOST; P58215; -.
DR   MassIVE; P58215; -.
DR   PaxDb; P58215; -.
DR   PeptideAtlas; P58215; -.
DR   ProteomicsDB; 57056; -. [P58215-1]
DR   ProteomicsDB; 66450; -.
DR   Antibodypedia; 31582; 200 antibodies from 22 providers.
DR   DNASU; 84695; -.
DR   Ensembl; ENST00000264094.8; ENSP00000264094.3; ENSG00000115318.12. [P58215-1]
DR   Ensembl; ENST00000393937.6; ENSP00000377512.2; ENSG00000115318.12. [P58215-3]
DR   GeneID; 84695; -.
DR   KEGG; hsa:84695; -.
DR   MANE-Select; ENST00000264094.8; ENSP00000264094.3; NM_032603.5; NP_115992.1.
DR   UCSC; uc002smp.3; human. [P58215-1]
DR   AGR; HGNC:13869; -.
DR   CTD; 84695; -.
DR   DisGeNET; 84695; -.
DR   GeneCards; LOXL3; -.
DR   HGNC; HGNC:13869; LOXL3.
DR   HPA; ENSG00000115318; Low tissue specificity.
DR   MalaCards; LOXL3; -.
DR   MIM; 607163; gene.
DR   MIM; 619781; phenotype.
DR   neXtProt; NX_P58215; -.
DR   OpenTargets; ENSG00000115318; -.
DR   Orphanet; 250984; Autosomal recessive Stickler syndrome.
DR   PharmGKB; PA30430; -.
DR   VEuPathDB; HostDB:ENSG00000115318; -.
DR   eggNOG; ENOG502QSX8; Eukaryota.
DR   GeneTree; ENSGT00940000158157; -.
DR   InParanoid; P58215; -.
DR   OMA; HWGLICG; -.
DR   OrthoDB; 3035117at2759; -.
DR   PhylomeDB; P58215; -.
DR   TreeFam; TF326061; -.
DR   BioCyc; MetaCyc:ENSG00000115318-MON; -.
DR   BRENDA; 1.4.3.13; 2681.
DR   PathwayCommons; P58215; -.
DR   Reactome; R-HSA-1566948; Elastic fibre formation.
DR   Reactome; R-HSA-2243919; Crosslinking of collagen fibrils.
DR   SignaLink; P58215; -.
DR   BioGRID-ORCS; 84695; 10 hits in 1151 CRISPR screens.
DR   ChiTaRS; LOXL3; human.
DR   GeneWiki; LOXL3; -.
DR   GenomeRNAi; 84695; -.
DR   Pharos; P58215; Tchem.
DR   PRO; PR:P58215; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P58215; protein.
DR   Bgee; ENSG00000115318; Expressed in tibia and 140 other tissues.
DR   ExpressionAtlas; P58215; baseline and differential.
DR   Genevisible; P58215; HS.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; NAS:UniProtKB.
DR   GO; GO:0001968; F:fibronectin binding; ISS:UniProtKB.
DR   GO; GO:0004720; F:protein-lysine 6-oxidase activity; IDA:UniProtKB.
DR   GO; GO:0005044; F:scavenger receptor activity; IEA:InterPro.
DR   GO; GO:0030199; P:collagen fibril organization; IBA:GO_Central.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:1905590; P:fibronectin fibril organization; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0030324; P:lung development; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:2000329; P:negative regulation of T-helper 17 cell lineage commitment; ISS:UniProtKB.
DR   GO; GO:0018057; P:peptidyl-lysine oxidation; IDA:UniProtKB.
DR   GO; GO:2001046; P:positive regulation of integrin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060021; P:roof of mouth development; ISS:UniProtKB.
DR   GO; GO:0061053; P:somite development; ISS:UniProtKB.
DR   GO; GO:0021510; P:spinal cord development; ISS:UniProtKB.
DR   Gene3D; 3.10.250.10; SRCR-like domain; 4.
DR   InterPro; IPR001695; Lysyl_oxidase.
DR   InterPro; IPR019828; Lysyl_oxidase_CS.
DR   InterPro; IPR001190; SRCR.
DR   InterPro; IPR017448; SRCR-like_dom.
DR   InterPro; IPR036772; SRCR-like_dom_sf.
DR   PANTHER; PTHR45817:SF2; LYSYL OXIDASE HOMOLOG 3; 1.
DR   PANTHER; PTHR45817; LYSYL OXIDASE-LIKE-RELATED; 1.
DR   Pfam; PF01186; Lysyl_oxidase; 1.
DR   Pfam; PF00530; SRCR; 4.
DR   PRINTS; PR00074; LYSYLOXIDASE.
DR   PRINTS; PR00258; SPERACTRCPTR.
DR   SMART; SM00202; SR; 4.
DR   SUPFAM; SSF56487; SRCR-like; 4.
DR   PROSITE; PS00926; LYSYL_OXIDASE; 1.
DR   PROSITE; PS00420; SRCR_1; 1.
DR   PROSITE; PS50287; SRCR_2; 4.
PE   1: Evidence at protein level;
KW   Alternative splicing; Copper; Cytoplasm; Deafness; Disulfide bond;
KW   Glycoprotein; Inflammatory response; LTQ; Metal-binding; Nucleus;
KW   Oxidoreductase; Reference proteome; Repeat; Secreted; Signal;
KW   Stickler syndrome; TPQ.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..753
FT                   /note="Lysyl oxidase homolog 3"
FT                   /id="PRO_0000018533"
FT   DOMAIN          44..145
FT                   /note="SRCR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DOMAIN          169..282
FT                   /note="SRCR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DOMAIN          307..407
FT                   /note="SRCR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DOMAIN          417..525
FT                   /note="SRCR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   REGION          290..315
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          529..732
FT                   /note="Lysyl-oxidase like"
FT   BINDING         607
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /evidence="ECO:0000255"
FT   BINDING         609
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /evidence="ECO:0000255"
FT   BINDING         611
FT                   /ligand="Cu cation"
FT                   /ligand_id="ChEBI:CHEBI:23378"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         670
FT                   /note="2',4',5'-topaquinone"
FT                   /evidence="ECO:0000250|UniProtKB:P33072"
FT   CARBOHYD        111
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        266
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        390
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        481
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        625
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        70..134
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        83..144
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        114..124
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        201..271
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        214..281
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        248..258
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        332..396
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        345..406
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        376..386
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        446..511
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        459..524
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        492..502
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        554..560
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        606..654
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        638..644
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        666..676
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   DISULFID        713..727
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00196"
FT   CROSSLNK        634..670
FT                   /note="Lysine tyrosylquinone (Lys-Tyr)"
FT                   /evidence="ECO:0000250|UniProtKB:P33072"
FT   VAR_SEQ         1..361
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17018530"
FT                   /id="VSP_054417"
FT   VAR_SEQ         159..303
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054418"
FT   VARIANT         615
FT                   /note="I -> F (in dbSNP:rs17010021)"
FT                   /id="VAR_050011"
FT   VARIANT         676
FT                   /note="C -> Y (found in patients with Stickler syndrome;
FT                   unknown pathological significance; dbSNP:rs786204838)"
FT                   /evidence="ECO:0000269|PubMed:25663169"
FT                   /id="VAR_077909"
FT   MUTAGEN         83
FT                   /note="C->A: Impaired ability to mediate deacetylation of
FT                   STAT3; when associated with A-214; A-345 and A-459."
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MUTAGEN         214
FT                   /note="C->A: Impaired ability to mediate deacetylation of
FT                   STAT3; when associated with A-83; A-345 and A-459."
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MUTAGEN         345
FT                   /note="C->A: Impaired ability to mediate deacetylation of
FT                   STAT3; when associated with A-83; A-214 and A-459."
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MUTAGEN         376
FT                   /note="C->A: Impaired ability to mediate deacetylation of
FT                   STAT3; when associated with A-446 and A-492."
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MUTAGEN         446
FT                   /note="C->A: Impaired ability to mediate deacetylation of
FT                   STAT3; when associated with A-376 and A-492."
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MUTAGEN         459
FT                   /note="C->A: Impaired ability to mediate deacetylation of
FT                   STAT3; when associated with A-83; A-214 and A-345."
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MUTAGEN         492
FT                   /note="C->A: Impaired ability to mediate deacetylation of
FT                   STAT3; when associated with A-376 and A-446."
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   MUTAGEN         607..609
FT                   /note="HGH->QGQ: Impaired ability to mediate deacetylation
FT                   of STAT3."
FT                   /evidence="ECO:0000269|PubMed:28065600"
FT   CONFLICT        159
FT                   /note="E -> K (in Ref. 3; AAK91134)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   753 AA;  83166 MW;  582C46DA25E05A69 CRC64;
     MRPVSVWQWS PWGLLLCLLC SSCLGSPSPS TGPEKKAGSQ GLRFRLAGFP RKPYEGRVEI
     QRAGEWGTIC DDDFTLQAAH ILCRELGFTE ATGWTHSAKY GPGTGRIWLD NLSCSGTEQS
     VTECASRGWG NSDCTHDEDA GVICKDQRLP GFSDSNVIEV EHHLQVEEVR IRPAVGWGRR
     PLPVTEGLVE VRLPDGWSQV CDKGWSAHNS HVVCGMLGFP SEKRVNAAFY RLLAQRQQHS
     FGLHGVACVG TEAHLSLCSL EFYRANDTAR CPGGGPAVVS CVPGPVYAAS SGQKKQQQSK
     PQGEARVRLK GGAHPGEGRV EVLKASTWGT VCDRKWDLHA ASVVCRELGF GSAREALSGA
     RMGQGMGAIH LSEVRCSGQE LSLWKCPHKN ITAEDCSHSQ DAGVRCNLPY TGAETRIRLS
     GGRSQHEGRV EVQIGGPGPL RWGLICGDDW GTLEAMVACR QLGLGYANHG LQETWYWDSG
     NITEVVMSGV RCTGTELSLD QCAHHGTHIT CKRTGTRFTA GVICSETASD LLLHSALVQE
     TAYIEDRPLH MLYCAAEENC LASSARSANW PYGHRRLLRF SSQIHNLGRA DFRPKAGRHS
     WVWHECHGHY HSMDIFTHYD ILTPNGTKVA EGHKASFCLE DTECQEDVSK RYECANFGEQ
     GITVGCWDLY RHDIDCQWID ITDVKPGNYI LQVVINPNFE VAESDFTNNA MKCNCKYDGH
     RIWVHNCHIG DAFSEEANRR FERYPGQTSN QII
//
